Amber Y. Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Amber Y. Song has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Cheryl A. Jones
Center for Vaccines and Immunology, University of Georgia, Athens, GA 30605, USA
1 shared publication - Lynn Bimler
Department of Immunology and Microbiology, the Scripps Research Institute, La Jolla, CA 92037, USA
1 shared publication - Scott K. Johnson
Center for Vaccines and Immunology, University of Georgia, Athens, GA 30605, USA
1 shared publication - Silke Paust
The Jackson Laboratory for Genomic Medicine, United States
1 shared publication - Stephen Mark Tompkins
Department of Infectious Diseases, University of Georgia College of Veterinary Medicine, Athens, Georgia, USA
1 shared publication - Sydney L. Ronzulli
Influenza Division, National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA
1 shared publication
Latest Publications
- Open Access
- 12 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (37) , eadx3505
Non-neutralizing antibodies to influenza A matrix-protein-2-ectodomain are broadly effective therapeutics and resistant to viral escape mutations
Influenza A viruses remain a global health threat, yet no universal antibody therapy exists. Clinical programs have centered on neutralizing mAbs, only to be thwarted by strain specificity and rapid viral escape. We instead engineered three non-neutralizing IgG2a mAbs that target distinct, overlapping epitopes within the conserved N terminus of the M2 ectodomain (M2e). Combined at low dose, this “triple M2e-mAb” confers robust prophylactic and therapeutic protection in mice challenged with diverse human and zoonotic IAV strains, including highly pathogenic variants. Therapeutic efficacy depends on Fc-mediated effector activity via FcγRI, FcγRIII, and FcγRIV, rather than in vitro neutralization. Serial passaging in triple M2e-mAb–treated immunocompetent and immunodeficient hosts failed to generate viral escape mutants. Our findings redefine the influenza-specific antibody therapeutic design and support Fc-optimized, non-neutralizing M2e-mAbs as a broadly effective, mutation-resistant, off-the-shelve therapy with direct relevance to human pandemic preparedness.
- 12 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (37) , eadx3505
Open AccessNon-neutralizing antibodies to influenza A matrix-protein-2-ectodomain are broadly effective therapeutics and resistant to viral escape mutations
Influenza A viruses remain a global health threat, yet no universal antibody therapy exists. Clinical programs have centered on neutralizing mAbs, only to be thwarted by strain specificity and rapid viral escape. We instead engineered three non-neutralizing IgG2a mAbs that target distinct, overlapping epitopes within the conserved N terminus of the M2 ectodomain (M2e). Combined at low dose, this “triple M2e-mAb” confers robust prophylactic and therapeutic protection in mice challenged with diverse human and zoonotic IAV strains, including highly pathogenic variants. Therapeutic efficacy depends on Fc-mediated effector activity via FcγRI, FcγRIII, and FcγRIV, rather than in vitro neutralization. Serial passaging in triple M2e-mAb–treated immunocompetent and immunodeficient hosts failed to generate viral escape mutants. Our findings redefine the influenza-specific antibody therapeutic design and support Fc-optimized, non-neutralizing M2e-mAbs as a broadly effective, mutation-resistant, off-the-shelve therapy with direct relevance to human pandemic preparedness.